• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Canadian Journal of Neurological Sciences: le Journal Canadien des Sciences Neurologiques >Management of Parkinson's disease a review of current and new therapies.
【24h】

Management of Parkinson's disease a review of current and new therapies.

机译：帕金森氏病的治疗方法综述。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The management of Parkinson's disease has undergone recent changes with the advent of new therapies, both pharmacotherapy and surgery. Available interventions are discussed. Levodopa remains the mainstay of therapy. New drugs include the dopamine agonists and COMT inhibitors. New dopamine agonists which may have a levodopa "sparing effect;" it has been suggested that some of the drugs should be considered as first line treatments for newly diagnosed Parkinson's disease patients. We review roles of these drugs. The concept of neuroprotection in neurodegenerative disorders such as Parkinson's disease became popular in the mid 1980s and it is hoped that eventually therapy will be directed at slowing progression of the disease. A great deal more work needs to be done before a suitable agent is identified as being neuroprotective. Potential neuroprotective agents are reviewed. Surgical therapies for Parkinson's disease consisting of various forms of lesion surgery as well as stimulation procedures are reviewed. Complications of drug therapy include motor problems such as motor response fluctuations, as well as psychiatric complications including levodopa-induced psychosis. Atypical neuroleptic agents and ECT for psychiatric syndromes associated with Parkinson's disease are discussed. Algorithms for the management of early disease as well as the management of psychosis in Parkinson's disease are included. Treatment options for advanced disease are tabulated.
机译：随着药物，手术等新疗法的出现，帕金森氏病的治疗方法发生了新的变化。讨论了可用的干预措施。左旋多巴仍然是治疗的主体。新药包括多巴胺激动剂和COMT抑制剂。可能具有左旋多巴“保留作用”的新型多巴胺激动剂;有人建议对新诊断的帕金森氏病患者应考虑将某些药物作为一线治疗。我们回顾了这些药物的作用。在诸如帕金森氏病的神经退行性疾病中，神经保护的概念在1980年代中期开始流行，人们希望最终的治疗将针对该疾病的发展。在确定一种合适的药物具有神经保护作用之前，还需要做大量的工作。审查了潜在的神经保护剂。帕金森氏病的外科治疗包括各种形式的病变手术以及刺激程序进行了审查。药物治疗的并发症包括运动问题，例如运动反应波动，以及精神病并发症，包括左旋多巴诱发的精神病。讨论了与帕金森氏病有关的精神病综合症的非典型抗精神病药和ECT。包括用于早期疾病管理和帕金森氏病精神病管理的算法。表中列出了晚期疾病的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号